Disclosure 0001810417-26-000023-2

SEC FORM 4

$202,437.40

Avalo Therapeutics, Inc. (AVTX)

Sale of 12,394 shares at $16.3335 per share.

Reporting Person Sullivan Christopher Ryan · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 18, 2026

Source: SEC Form 4 · 0001810417-26-000023 · filed 2026-09-18 · View filing →

Composed from the Form 4 as filed with the SEC. Share counts, prices and dates are the filing's own; the disclosure lag is counted in business days from the transaction date to the filing date. What is a Form 4?

Cite this card

Desq Long. "Avalo Therapeutics, Inc. (AVTX)." Disclosed 2026-09-18. https://desqlong.com/cards/0001810417-26-000023-2 (retrieved 2026-09-26).